Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Volution FY adjusted EPS seen 'slightly ahead' of consensus

(Sharecast News) - Ventilation products group Volution said on Thursday that it has made "continued good progress" in the year ending 31 July and now expects adjusted earnings per share to be "slightly ahead" of current consensus estimates of 32.00p. Volution expects to deliver FY organic revenue growth of more than 5% on a constant currency basis, up from 4% at the half year, while total group revenues were seen more than 20% higher at constant currency, boosted by eight months contribution from Fantech, which was acquired in December 2024.

The FTSE 250-listed firm also expects adjusted operating margins to be "broadly in line with the first half of the year", with operating margins on an organic basis expected to increase modestly, offset by the inorganic dilution from the acquisition of Fantech.

However, Volution did acknowledge that the weakening of overseas currencies, most notably the Australian and New Zealand dollars, had created "a negative translation impact" of approximately £5.0m to revenue and just over £1.0m to adjusted operating profits.

Chief executive Ronnie George said: "Volution has delivered good progress during the second half of the year with organic growth expected to be slightly ahead of our target range of 3-5%.

"Given our good progress in the second half of the year, the board now expects adjusted earnings per share to be slightly ahead of current market consensus for FY25."

As of 1015 BST, Volution shares were up 3.64% at 654.00p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.